Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Reg FD section contains only forward-looking-statement cautionary language, not substantive operating or financial disclosure.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD section contains only forward-looking-statement cautionary language, not substantive operating or financial disclosure
- Risks highlighted for ReSPECT and partner clinical-trial data, including changing topline results and differing interpretations
- Key commercialization risks: product utilization, pricing pressure, reimbursement, patient access, and generic or biosimilar competition
- Clinical development remains exposed to enrollment shortfalls, unexpected safety or efficacy findings, and regulatory approval uncertainty
Item EX-99.1 · Exhibit EX-99.1
- Phase III ReSPECT met FDA and EMA primary endpoint, demonstrating non-inferiority in fungal-free survival at Day 90
- Fungal-free survival 60.7% with rezafungin versus 59.0% with standard antimicrobial regimen
- Comparable efficacy and mortality across Candida, Aspergillus, and Pneumocystis infections
- Favorable secondary safety outcomes, including fewer toxicity-related discontinuations and drug-drug interactions
- Pre-NDA FDA meeting anticipated in coming months, with supplemental NDA submission targeted for 2H26; estimated U.S. opportunity exceeds $2 billion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.